Report provides single comprehensive source of information for pharma and biotech companies about suppliers of screening compounds for drug discovery
Screening compounds are the starting point for new blockbuster drugs.
Many new sources of unique compounds - both synthesised and from natural sources - have emerged over the past few years, notably companies from the former Soviet bloc countries.
To date there has been no single comprehensive source of information for pharma and biotech companies to consult to ensure they have the widest possible choice of these valuable drug candidates.
Select Biosciences says it now provides this information in its new report, 'The Directory of Molecular Diversity Suppliers'.
Personally compiled by Wendy Warr, one of the world's leading consultants to the chemistry marketplace, the report includes an analysis of trends in high throughput chemistry, screening and lead optimisation.
The majority of the 130 page directory comprises profiles of over 90 companies supplying building blocks, screening compounds, synthetic libraries, natural products and ancillary services to the pharmaceutical and biotechnology markets.
